Loading clinical trials...
Loading clinical trials...
A Randomized, Double-Blind, Multicenter, 3 Stage, Efficacy and Safety Study of NI-071 and US-Licensed Remicade® (Infliximab) for the Treatment of Patients With Rheumatoid Arthritis
Conditions
Interventions
NI-071
Remicade
Locations
134
United States
Nichi-Iko Investigational Site
Little Rock, Arkansas, United States
Nichi-Iko Investigational Site
Los Angeles, California, United States
Nichi-Iko Investigational Site
Los Angeles, California, United States
Nichi-Iko Investigational Site
Ventura, California, United States
Nichi-Iko Investigational Site
Whittier, California, United States
Nichi-Iko Investigational Site
Hamden, Connecticut, United States
Start Date
January 19, 2017
Primary Completion Date
May 20, 2019
Completion Date
May 20, 2019
Last Updated
January 30, 2023
NCT07536529
NCT06329401
NCT07048197
NCT06647069
NCT07484243
NCT06841562
Lead Sponsor
Nichi-Iko Pharmaceutical Co., Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions